Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
Key facts
- Where
- Birmingham, Camden, Charleston, Chicago, Detroit, Grand Rapids, Iowa City, Los Angeles, and San Diego, United StatesSee the 12 sites
Where in United States
- University of Alabama BirminghamBirmingham, United StatesContact: Rachel CopperTaking people
- The Cooper Health SystemCamden, United StatesContact: Clare HansonTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Betty OswaldTaking people
- Reproductive Genetics InstituteChicago, United StatesContact: Denise GinsbergTaking people
- Henry Ford HospitalDetroit, United StatesContact: Ellen MartindellTaking people
- Spectrum HealthGrand Rapids, United StatesContact: Yvonne EdgerlyTaking people
- University of Iowa Health CareIowa City, United StatesContact: Diedre FleenerTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Deebra Smith, MDTaking people
- Sharp-Rees Stealy Medical GroupSan Diego, United StatesContact: Mary LaPageTaking people
- Specialty Obstetrics of San DiegoSan Diego, United StatesContact: Deborah MaloneTaking people
- UCSDSan Diego, United StatesContact: Jason ChibuckTaking people
- Women's Health Care ResearchSan Diego, United StatesContact: Nora MartinezTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sequenom, Inc.
- Trial code
- NCT01429389
- Record updated
- 9 September 2026
- Original description
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.Read full original descriptionShow less
Collection of Whole Blood Specimens From Pregnant Women at Increased Risk of Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted From Maternal Plasma
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Inclusion: pregnant between 10 and 22 weeks gestation; 18 years of age or older; provides signed and dated informed consent; subject is at increased risk for fetal aneuploidy; subject is willing to undergo a CVS and/or amniocentesis procedure for the purpose of genetic analysis; subject agrees to provide the genetic results of the invasive procedure.
Exclusion: Previous sample donation under this protocol; Fetal demise at time of specimen sampling.